Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

With $76M series B, BlackThorn looks to build out neurobehavioral platform

How BlackThorn rebounded from a January clinical setback to raise $76 million to develop its targeted therapies for neurobehavioral disorders

Inhua Muijrers-Chen, Associate Editor
June 13, 2019 12:31 PM UTC

BlackThorn has amassed a $76 million series B round from investors who are banking on the potential of its PathFinder platform to circumvent the issue of patient heterogeneity in neurobehavioral disorders.

New investors Polaris Partners, Premier Partners, Scripps Research and Vertex Ventures HC participated in the round alongside existing investors Alexandria Venture Investments, Altitude Life Science Ventures, Arch Venture Partners, Biomatics Capital, GV, Johnson & Johnson Innovation -- JJDC Inc. and Mercury Fund. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

BlackThorn Therapeutics Inc.